PortalsOS

Now I worry about long COVID. Now I worry about what is this virus doing in our body now. Now we get into this idea, is it the vaccine or is it the virus? I don't know because both of them have spike protein.

Three weeks later, I see in the press that Johnson & Johnson is about to get priority review by the agency for chemotherapy in the bladder.

The drug Cerolimus, originally for organ transplant rejection, has kept Dr. Fagenbaum in remission for over 11 years.

We've done this with healthy volunteers already. More importantly, the NCI then designated us to treat patients without cancer, i.e. patients with what we call Lynch syndrome.

It's incongruous to me that you can priority review for chemotherapy and not priority review for a biologic that is safe.

The FDA refused to file our data for bladder cancer treatment, even though we have patients alive and cancer-free for 10 years. It's mystifying!

We injected this in 8,000. And what kind of response rate have you seen from the people who do have a cancer? Metastatic pancreatic cancer. Patients now alive, still six years.

The review process took two and a half years. It just got approved. This is why I said this president, and you and I talked about it, in his presidency could inform the world and the FDA that there's a breakthrough for all tumor types.

Each trial costs $200 to $300 million. Oh, really? Yes. And how many people do you need? 200 to 500. Oh, boy. Per trial.

If you go to csfifm.org or .com, you will see the trials that I'm now open as randomized trials. So we're now taking patients with lung cancer who failed in.